CN Patent

CN113769098B — MLL-menin抑制剂组合物在制备抗肝癌药物中的应用

Assigned to Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center · Expires 2022-09-30 · 4y expired

What this patent protects

本发明提供MLL‑menin抑制剂组合物在制备抗肝癌药物中的应用，所述组合物由MLL‑menin抑制剂与紫杉醇组成。本发明组合物通过抑制MLL催化H3K4me3，从而降低CYP1B1的表达量，增强紫杉醇对微管蛋白的结合作用，协同增加体外肝细胞癌细胞系和体内肝细胞癌小鼠对紫杉醇的敏感性，使得对紫杉醇高度耐药、单用表观遗传药物MLL‑menin抑制剂无效的肝细胞癌经过组合物治疗后显著提高化疗疗效。本发明组合物为耐紫杉醇治疗的肝细胞癌提供新的化疗药物。

USPTO Abstract

本发明提供MLL‑menin抑制剂组合物在制备抗肝癌药物中的应用，所述组合物由MLL‑menin抑制剂与紫杉醇组成。本发明组合物通过抑制MLL催化H3K4me3，从而降低CYP1B1的表达量，增强紫杉醇对微管蛋白的结合作用，协同增加体外肝细胞癌细胞系和体内肝细胞癌小鼠对紫杉醇的敏感性，使得对紫杉醇高度耐药、单用表观遗传药物MLL‑menin抑制剂无效的肝细胞癌经过组合物治疗后显著提高化疗疗效。本发明组合物为耐紫杉醇治疗的肝细胞癌提供新的化疗药物。

Drugs covered by this patent

Patent Metadata

Patent number
CN113769098B
Jurisdiction
CN
Classification
—
Expires
2022-09-30
Drug substance claim
No
Drug product claim
No
Assignee
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.